Cencora’s Quiet Power: Consistent Growth in a Tight-Margin World

Cencora (COR) is not a stock that will grab attention with flashy margins or a dramatic story.

For the real story, you have to go beyond the headlines.

This is a pharmaceutical distributor that runs a high-volume, thin-margin operation, which means the headline numbers can be a tad misleading. Revenue has climbed to more than $300B in 2025, while profitability looks deceptively modest at first glance.

To understand why this matters, you have to get into the details and lean into how scale, contracts and execution translate to top line power.

Today, we’ll do just that by looking at how the narrow margins have held the stock back, and why the underlying fundamentals are where you want to focus. With double-digit 5-year average growth, positive earnings growth, and consistent margins, there are several reasons this is a stock that should be on your radar – especially after the recent double-digit share price decline.

Let’s dive in…

Strong business, thin margins

Cencora is a dominant pharmaceutical distributor in the U.S. The company’s footprint spans branded and generic drugs, injectable pharmaceuticals, over-the-counter healthcare products and much more.

The company generated $321B in revenue in 2025 and runs a global network serving tens of thousands of providers, with 51,000 employees and specialty facilities, including cold-chain capacity to support high-growth therapies.

Revenue growth has seen steady growth at 7.5% YoY and 11% for the 5-year average. The forecast show that is expected to continue through 2026 and 2027.

The consistency you see in revenues doesn’t trickle down the same to earnings. In earnings, we see a lot more volatility, but the bright spot is the buoyancy to stay above the zero line.

After beating estimates for the last four quarters, the next four quarters are all forecasting growth.

Digging into the real story

Beyond the numbers, which show a picture of consistent growth and underlying profitability, is the intrinsic side of things that you can’t necessarily measure. The customer entrenchment and execution by the company are just as important.

Long-term, the company has locked down multi-billion contracts with large retail partners like Walgreens Boots Alliance, which represented roughly 24% of revenue in 2025. This agreement extends through 2029.

In the first quarter of 2026, Cencora completed the acquisition of OneOncology, a leading management services organization for oncology practices. This forced the company to raise adjusted operating income guidance to 11.5%-13.5%, from a range of 8%-10%. Strength in the U.S. Healthcare Solutions segment with a %5 increase in revenue in Q1 also supported the increase to guidance.

The bottom line

The bull case for Cencora is straight forward. It’s built on scale, discipline and contract visibility that have translated into steady revenue and double-digit adjusted earnings growth. The bear case is essentially the patience needed to withstand thin margins and headlines that don’t capture the full picture.

With guidance getting a boost after Q1 thanks to integrating higher‑margin specialty assets like OneOncology, forward earnings power is seeing improvement despite cooler investment sentiment.

The disconnect between perception and fundamentals is what presents those with a bull case over the long-term an excellent opportunity after the recent decline.

Insights by Sigmanomics

After the recent price decline, many investors are looking for buying opportunities.

Our proprietary forecast and trade setup dashboard at Sigmanomics is putting the pause on that rebound rally. As of 4/13/2026, the 7-day, 14-day and 28-day forecast are all showing a Bearish trade bias.

Take a look:

With all three aligned, now is not the time to go bottom fishing on a dip. Instead, let’s continue to show patience on COR and wait for, at a minimum, the 28-day forecasting turning bullish before we look to go long.